Condition
Pirtobrutinib
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07744724Phase 2Not Yet Recruiting
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
NCT07744737Phase 2Not Yet Recruiting
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
NCT07416890Phase 2RecruitingPrimary
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Showing all 3 trials